Nucleonics, Inc.

1953 was an extraordinary year for biology, an annus mirabilis, or wonder year, which offered scientific insights to rival those made by Einstein almost half a century earlier. It was in this year tha

It isn’t uncommon for a drug candidate to outlive the company that first sought to develop it. But the tortuous path of the preclinical RNA interference candidate against hepatitis C virus (HCV), TT-0

Investors’ and Big Pharmas’ hitherto frosty view of gene-based medicines may be starting to thaw, at least in places, warmed by clinical progress and a smattering of deals. But until the first FDA app

Though apparently dominated by Alnylam and Merck, the RNAi space is enjoying a surge of investment, newcomers, and INDs. Is there freedom to operate or are companies and their backers counting on bein